Pfizer Korea and Hanlim MS, Joint Sales Agreement Following Xeljanz
Second Partnership Agreement, Undertaking Diverse Activities Including Marketing and Sales
On April 2nd, Pfizer Korea, led by CEO Dongwook Oh, announced the signing of a joint sales contract with Hanlim MS, under CEO Vice Chairman Jung-Jin Kim, for Enbrel, a TNF (anti-tumor necrosis factor)-α inhibitor crucial in rheumatoid arthritis treatment.
The agreement aims to bolster marketing and sales efforts, ensuring broader access to Enbrel treatment for patients. Both companies plan to enhance synergies in the inflammation and immunological disease business, building upon their joint sales agreement for Xeljanz in February 2024.
Hanlim MS, having evolved from its Rheumatology Business Unit established in 2010 to an "Immunology Business Division" by 2024, brings significant expertise in distributing therapeutic agents for inflammatory and immune-mediated diseases to the partnership.
Enbrel, approved by the U.S. FDA in 1998 for rheumatoid arthritis treatment, holds indications for six conditions and has amassed over 8 million patient-years of experience globally as of February 2023.
Pfizer Korea's CEO, Dongwook Oh, underscores their commitment to enhancing patient convenience and treatment adherence, expressing confidence in Hanlim MS's expertise to further strengthen strategic collaboration.
CEO Vice Chairman Kim Jung-jin of Hanlim MS highlights the significance of offering diverse treatment options for autoimmune diseases, providing hope to patients.
With formulations like Enbrel injection 25 mg, Enbrel 50 mg prefilled syringe, and Enbrel Myclic pen 50 mg, Enbrel boasts a confirmed safety profile and long-term efficacy in rheumatic patient care, ensuring effective treatment options.